We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-0.95%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$55.7B
AUM Growth
+$1.33B
Cap. Flow
+$2.27B
Cap. Flow %
4.08%
Top 10 Hldgs %
19.71%
Holding
3,688
New
269
Increased
1,855
Reduced
1,236
Closed
227

Sector Composition

Rank Sector Weight
1 Technology 10.05%
2 Financials 9.3%
3 Healthcare 7.74%
4 Industrials 6.94%
5 Communication Services 5.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CULP icon
2951
Culp Inc
CULP
$43.7M
$263K ﹤0.01%
8,607
+79
+0.9% +$2.41K
MLCO icon
2952
Melco Resorts & Entertainment
MLCO
$2.14B
$263K ﹤0.01%
9,064
-1,151
-11% -$32.2K
INCO icon
2953
Columbia India Consumer ETF
INCO
$238M
$262K ﹤0.01%
5,661
+783
+16% +$37.1K
PIM
2954
Franklin Master Intermediate Income Trust
PIM
$152M
$262K ﹤0.01%
55,841
-4,264
-7% -$20.3K
CHU
2955
DELISTED
China Unicom (HONG KONG) Limited
CHU
$262K ﹤0.01%
20,430
+5,034
+33% +$67.4K
CBT icon
2956
Cabot Corp
CBT
$4.53B
$261K ﹤0.01%
+4,683
New +$295K
FATE icon
2957
Fate Therapeutics
FATE
$316M
$261K ﹤0.01%
26,750
+3,725
+16% +$35.7K
FICO icon
2958
Fair Isaac
FICO
$22.2B
$261K ﹤0.01%
1,541
+14
+0.9% +$2.34K
GNBC
2959
DELISTED
Green Bancorp, Inc
GNBC
$261K ﹤0.01%
11,726
ARDC
2960
Are Dynamic Credit Allocation Fund
ARDC
$298M
$260K ﹤0.01%
16,021
-6,890
-30% -$112K
COLD icon
2961
Americold
COLD
$4.19B
$260K ﹤0.01%
+13,620
New +$246K
EINC icon
2962
VanEck Energy Income ETF
EINC
$79.4M
$260K ﹤0.01%
4,173
-260
-6% -$18.2K
LJPC
2963
DELISTED
La Jolla Pharmaceutical Company
LJPC
$260K ﹤0.01%
8,743
-32,133
-79% -$1.04M
DBE icon
2964
Invesco DB Energy Fund
DBE
$91.1M
$259K ﹤0.01%
16,965
+4,232
+33% +$62.6K
SGMO
2965
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$259K ﹤0.01%
+13,627
New +$291K
MDCO
2966
DELISTED
Medicines Co
MDCO
$258K ﹤0.01%
7,818
-3,139
-29% -$98.1K
TRMB icon
2967
Trimble
TRMB
$13.4B
$257K ﹤0.01%
7,153
+1,298
+22% +$52.3K
ONC
2968
BeOne Medicines Ltd
ONC
$40.9B
$257K ﹤0.01%
+1,529
New +$207K
ACNT icon
2969
Ascent Industries
ACNT
$141M
$256K ﹤0.01%
17,500
CGEN icon
2970
Compugen
CGEN
$225M
$256K ﹤0.01%
57,470
-680
-1% -$2.29K
IGD
2971
Voya Global Equity Dividend and Premium Opportunity Fund
IGD
$526M
$256K ﹤0.01%
35,074
-3,648
-9% -$27.8K
UI icon
2972
Ubiquiti
UI
$34.9B
$256K ﹤0.01%
3,727
-19,369
-84% -$1.38M
MDR
2973
DELISTED
McDermott International
MDR
$256K ﹤0.01%
14,021
+1,403
+11% +$32.1K
CLMT icon
2974
Calumet Specialty Products
CLMT
$4.1B
$255K ﹤0.01%
36,133
-2,020
-5% -$14.9K
COUP
2975
DELISTED
Coupa Software Incorporated
COUP
$255K ﹤0.01%
+5,599
New +$230K

Similar funds

Raymond James & Associates's Q1 2018 Portfolio in Review

As of Q1 2018, Raymond James & Associates held 3,688 positions worth $55.7B, up 2.4% from $54.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Raymond James & Associates deployed $2.27B of net new capital in Q1 2018, opening 269 new positions and adding to 1,855 existing holdings. Its largest new stake was Nutrien: 608,282 shares worth $28.7M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 9.7% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was AbbVie, an estimated $68.1M trimmed.

  • Raymond James & Associates's largest Q1 2018 buy was Nutrien: 608,282 shares worth $28.7M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q1 2018, an estimated $211M increase.
  • Raymond James & Associates's biggest Q1 2018 reduction was AbbVie, cutting an estimated $68.1M.
  • Raymond James & Associates fully exited Regal Entertainment Group in Q1 2018, selling an estimated $48.4M.
  • Raymond James & Associates's ten largest holdings make up 20% of its $55.7B portfolio in Q1 2018.
  • Raymond James & Associates opened 269 new positions and closed 227 in Q1 2018.
  • Raymond James & Associates's portfolio value rose 2.4% quarter-over-quarter to $55.7B.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.